These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 35063472)

  • 1. Three-Year Safety and Efficacy of the 0.19-mg Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Edema: The PALADIN Study.
    Singer MA; Sheth V; Mansour SE; Coughlin B; Gonzalez VH
    Ophthalmology; 2022 Jun; 129(6):605-613. PubMed ID: 35063472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The 0.19-mg Fluocinolone Acetonide Intravitreal Implant for Diabetic Macular Edema: Intraocular Pressure-Related Effects over 36 Months.
    Roth DB; Eichenbaum D; Malik D; Radcliffe NM; Cutino A; Small KW;
    Ophthalmol Retina; 2024 Jan; 8(1):49-54. PubMed ID: 37586482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The 0.19-mg Fluocinolone Acetonide Intravitreal Implant Reduces Treatment Burden in Diabetic Macular Edema.
    Merrill PT; Holekamp N; Roth D; Kasper J; Grigorian R;
    Am J Ophthalmol; 2023 Apr; 248():16-23. PubMed ID: 36223849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two-year interim safety results of the 0.2 µg/day fluocinolone acetonide intravitreal implant for the treatment of diabetic macular oedema: the observational PALADIN study.
    Mansour SE; Kiernan DF; Roth DB; Eichenbaum D; Holekamp NM; Kaba S; Werts E
    Br J Ophthalmol; 2021 Mar; 105(3):414-419. PubMed ID: 32461262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluocinolone Acetonide Intravitreal Implant 190 μg (ILUVIEN®) in Vitrectomized versus Nonvitrectomized Eyes for the Treatment of Chronic Diabetic Macular Edema.
    Pessoa B; Coelho J; Correia N; Ferreira N; Beirão M; Meireles A
    Ophthalmic Res; 2018; 59(2):68-75. PubMed ID: 29248913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The outcome of fluocinolone acetonide intravitreal implant is predicted by the response to dexamethasone implant in diabetic macular oedema.
    Cicinelli MV; Rosenblatt A; Grosso D; Zollet P; Capone L; Rabiolo A; Lattanzio R; Loewenstein A; Bandello F;
    Eye (Lond); 2021 Dec; 35(12):3232-3242. PubMed ID: 33479485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and safety of fluocinolone acetonide intravitreal implant in diabetic macular edema patients considered insufficiently responsive to available therapies (REACT): a prospective, non-randomized, and multicenter study.
    Ruiz-Moreno JM; Adán A; Lafuente M; Asencio Durán M; Arias Barquet L; García Layana A; Araiz Iribarren J
    Int Ophthalmol; 2023 Dec; 43(12):4639-4649. PubMed ID: 37697082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diabetic macular edema outcomes in eyes treated with fluocinolone acetonide 0.2 µg/d intravitreal implant: real-world UK experience.
    El-Ghrably I; Steel DHW; Habib M; Vaideanu-Collins D; Manvikar S; Hillier RJ
    Eur J Ophthalmol; 2017 May; 27(3):357-362. PubMed ID: 28165610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BETTER BASELINE VISION LEADS TO BETTER OUTCOMES AFTER THE 0.19-mg FLUOCINOLONE ACETONIDE INTRAVITREAL IMPLANT IN DIABETIC MACULAR EDEMA.
    Gonzalez VH; Luo C; Almeida DRP; Cutino A; Coughlin B; Kasper J; Kiernan DF; ; ;
    Retina; 2023 Aug; 43(8):1301-1307. PubMed ID: 37130434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Outcomes of Switching from Short- to Long-Term Intravitreal Corticosteroid Implant Therapy in Patients with Diabetic Macular Edema.
    Vaz-Pereira S; Castro-de-Sousa JP; Martins D; Prates Canelas J; Reis P; Sampaio A; Urbano H; Kaku P; Nascimento J; Marques-Neves C
    Ophthalmic Res; 2020; 63(2):114-121. PubMed ID: 31801148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravitreal steroids for macular edema in diabetes.
    Rittiphairoj T; Mir TA; Li T; Virgili G
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005656. PubMed ID: 33206392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of data characterizing the clinical effectiveness of the fluocinolone intravitreal implant (ILUVIEN) in patients with diabetic macular edema from the real world, non-interventional ICE-UK study and the FAME randomized controlled trials.
    Holden SE; Kapik B; Beiderbeck AB; Currie CJ
    Curr Med Res Opin; 2019 Jul; 35(7):1165-1176. PubMed ID: 30569759
    [No Abstract]   [Full Text] [Related]  

  • 13. Three-year results from the Retro-IDEAL study: Real-world data from diabetic macular edema (DME) patients treated with ILUVIEN
    Augustin AJ; Bopp S; Fechner M; Holz F; Sandner D; Winkgen AM; Khoramnia R; Neuhann T; Warscher M; Spitzer M; Sekundo W; Seitz B; Duncker T; Ksinsik C; Höh H; Gentsch D
    Eur J Ophthalmol; 2020 Mar; 30(2):382-391. PubMed ID: 30884972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and tolerability of the fluocinolone acetonide implant in patients with diabetic macular edema in UAE: 12-Month results.
    Elbarky AM
    Eur J Ophthalmol; 2021 Nov; 31(6):3196-3202. PubMed ID: 33426902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in Ganglion Cell Layer Thickness after Treatment with the 0.2 µg/day Fluocinolone Acetonide Implant in Vitrectomized and Nonvitrectomized Eyes with Diabetic Macular Edema.
    Pessoa B; Castro C; Ferreira A; Leite J; Heitor J; Menéres P; Figueira J; Meireles A; Beirão JM
    Ophthalmic Res; 2022; 65(3):310-320. PubMed ID: 35086095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ILUVIEN
    Teixeira C; Pessoa B; Ruão M; Sousa JPC; Penas S; Silva R; Carneiro Â; Meireles A
    Eur J Ophthalmol; 2024 Jul; 34(4):1149-1158. PubMed ID: 38013451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes in diabetic macular edema switched directly or after a dexamethasone implant to a fluocinolone acetonide intravitreal implant following anti-VEGF treatment.
    Rehak M; Busch C; Unterlauft JD; Jochmann C; Wiedemann P
    Acta Diabetol; 2020 Apr; 57(4):469-478. PubMed ID: 31749051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the clinical effectiveness of fluocinolone acetonide 190 µg intravitreal implant in diabetic macular edema: a comparison between study and fellow eyes.
    Currie CJ; Holden SE; Berni E; Owens DR
    Curr Med Res Opin; 2017 Oct; 33(sup2):19-31. PubMed ID: 28881143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitreous cytokine levels following the administration of a single 0.19 mg fluocinolone acetonide (ILUVIEN®) implant in patients with refractory diabetic macular edema (DME)-results from the ILUVIT study.
    Deuchler SK; Schubert R; Singh P; Chedid A; Kenikstul N; Scott J; Kohnen T; Ackermann H; Koch F
    Graefes Arch Clin Exp Ophthalmol; 2022 Aug; 260(8):2537-2547. PubMed ID: 35239010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of chronic diabetic macular oedema with intravitreal fluocinolone acetonide implant; real-life analysis of outcomes during overall treatment period.
    Cox L; Li Y; Fotuhi M; Vermeirsch S; Yeung I; Hamilton RD; Rajendram R; Lukic M
    Eur J Ophthalmol; 2022 Nov; 32(6):3629-3636. PubMed ID: 35484812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.